JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Protean Small Cap beat its benchmark in December. It returned 0.3%, while the index retracted by -0.1%. Click here to read ...

True, one of the drugmaker's leading candidates, CagriSema, recently failed to impress investors in a phase 3 study. Upon closer inspection, though, Novo Nordisk's "disappointing" late-stage ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will continue to deliver “beat-and-raise performances ...

J.P. Morgan has once again picked Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG) as its top large-cap picks in MedTech for the new year, and reaffirmed insulin pump maker ...

GLP-1 drugs are known to have a direct effect on the endothelial cells that line blood vessels, lymph vessels and the heart, providing a biologically plausible mechanism for the cardiovascular benefit ...

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD – Research Report), with a price target of $324.00. The company’s shares closed yesterday ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...